BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
Keyword: Programmed death ligand 1
1
Immune checkpoint inhibitors in the first-line treatment of esophageal squamous cell carcinoma: Minireview for a big shift
6/13/2025 1:39:37 PM | Browse: 208 | Download: 742
2
Assessment of programmed death-ligand 1 expression in primary tumors and paired lymph node metastases of gastric adenocarcinoma
3/12/2024 10:04:17 AM | Browse: 392 | Download: 983
3
Hepatic arterial infusion chemotherapy with/without anti-angiogenesis agents and immune checkpoint inhibitors for unresectable hepatocellular carcinoma and meta-analysis
1/26/2024 7:56:29 AM | Browse: 456 | Download: 1487
4
Immunotherapy against programmed death-1/programmed death ligand 1 in hepatocellular carcinoma: Importance of molecular variations, cellular heterogeneity, and cancer stem cells
7/23/2021 1:30:21 PM | Browse: 842 | Download: 1896
5
Programmed death 1, ligand 1 and 2 correlated genes and their association with mutation, immune infiltration and clinical outcomes of hepatocellular carcinoma
11/12/2020 3:59:23 AM | Browse: 949 | Download: 2407
6
Pathological significance of abnormal recepteur d’origine nantais and programmed death ligand 1 expression in colorectal cancer
11/12/2020 3:59:23 AM | Browse: 1129 | Download: 2718
7
Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas
4/13/2019 6:00:06 AM | Browse: 1063 | Download: 1815
8
Advances in immuno-oncology biomarkers for gastroesophageal cancer: Programmed death ligand 1, microsatellite instability, and beyond
7/5/2018 1:33:43 AM | Browse: 1128 | Download: 1638
Write to the Help Desk
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.